Utility of ferritin as a predictor of the patients with Kawasaki disease refractory to intravenous immunoglobulin therapy

References

• Burns JC, Glodé MP. Kawasaki syndrome. Lancet. 2004;364(9433): 533–44.
   PubMed Web of Science ®Google Scholar
• Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110(17):2747–71.
   PubMed Web of Science ®Google Scholar
• Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet. 1984;2(8411):1055–8.
   PubMed Web of Science ®Google Scholar
• Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, et al. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. Pediatr Infect Dis J. 2008;27(2):155–60.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006;113(22):2606–12.
   PubMed Web of Science ®Google Scholar
• Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, Matsuishi T. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2006;149(2):237–40.
   PubMed Web of Science ®Google Scholar
• Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr. 2007;166(2):131–7.
   PubMed Web of Science ®Google Scholar
• Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV. Serum ferritin: Past, present and future. Biochim Biophys Acta. 2010;1800(8):760–9.
   PubMed Web of Science ®Google Scholar
• Miller LL, Miller SC, Torti SV, Tsuji Y, Torti FM. Iron-independent induction of ferritin H chain by tumor necrosis factor. Proc Natl Acad Sci USA. 1991;88(11):4946–50.
   PubMed Web of Science ®Google Scholar
• Tsuji Y, Miller LL, Miller SC, Torti SV, Torti FM. Tumor necrosis factor-alpha and interleukin 1-alpha regulate transferrin receptor in human diploid fibroblasts. Relationship to the induction of ferritin heavy chain. J Biol Chem. 1991;266(11):7257–61.
   PubMed Web of Science ®Google Scholar
• Pelkonen P, Swanljung K, Siimes MA. Ferritinemia as an indicator of systemic disease activity in children with systemic juvenile rheumatoid arthritis. Acta Paediatr Scand. 1986;75(1):64–8.
   PubMed Web of Science ®Google Scholar
• Ayusawa M, Sonobe T, Uemura S, Ogawa S, Nakamura Y, Kiyosawa N, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int. 2005;47(2):232–4.
   PubMed Web of Science ®Google Scholar
• Kim HK, Kim HG, Cho SJ, Hong YM, Sohn S, Yoo ES, et al. Clinical characteristics of hemophagocytic lymphohistiocytosis related to Kawasaki disease. Pediatr Hematol Oncol. 2011;28(3):230–6.
   PubMed Web of Science ®Google Scholar
• Ohga S, Ooshima A, Fukushige J, Ueda K. Histiocytic haemophagocytosis in a patient with Kawasaki disease: changes in the hypercytokinaemic state. Eur J Pediatr. 1995;154(7):539–41.
   PubMed Web of Science ®Google Scholar
• Nasir A, Al Tatari H, Hamdan MA. Very high serum ferritin levels in three newborns with Kawasaki-like illness. Paediatr Child Health. 2012;17(4):201–4.
   PubMed Web of Science ®Google Scholar
• Naoe S, Takahashi K, Masuda H, Tanaka N. Kawasaki disease. With particular emphasis on arterial lesions. Acta Pathol Jpn. 1991; 41(11):785–97.
   PubMedGoogle Scholar
• Takahashi K, Oharaseki T, Yokouchi Y, Naoe S, Saji T. Kawasaki disease: basic and pathological findings. Clin Exp Nephrol. 2013;17(5):690–3.
   PubMed Web of Science ®Google Scholar
• Coffman LG, Parsonage D, D’Agostino R, Jr, Torti FM, Torti SV. Regulatory effects of ferritin on angiogenesis. Proc Natl Acad Sci USA. 2009;106(2):570–5.
   PubMed Web of Science ®Google Scholar
• Guo L, Jiang F, Tang YT, Si MY, Jiao XY. The association of serum vascular endothelial growth factor and ferritin in diabetic microvascular disease. Diabetes Technol Ther. 2014;16(4):224–34.
   PubMed Web of Science ®Google Scholar
• Ohno T, Yuge T, Kariyazono H, Igarashi H, Joh-o K, Kinugawa N, et al. Serum hepatocyte growth factor combined with vascular endothelial growth factor as a predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease. Eur J Pediatr. 2002;161(2):105–11.
   PubMed Web of Science ®Google Scholar
• Matsuda A, Morita H, Unno H, Saito H, Matsumoto K, Hirao Y, et al. Anti-inflammatory effects of high-dose IgG on TNF-α-activated human coronary artery endothelial cells. Eur J Immunol. 2012;42(8):2121–31.
   PubMed Web of Science ®Google Scholar
• Sleeper LA, Minich LL, McCrindle BM, Li JS, Mason W, Colan SD, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr. 2011;158(5):831–5.e3.
   PubMed Web of Science ®Google Scholar
• Burns JC, Herzog L, Fabri O, Tremoulet AH, Rodó X, Uehara R, et al. Seasonality of Kawasaki disease: a global perspective. PLoS One. 2013;8(9):e74529.
   PubMed Web of Science ®Google Scholar
• Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Eng J Med. 2007;356(7): 663–75.
   PubMed Web of Science ®Google Scholar
• Okada K, Hara J, Maki I, Miki K, Matsuzaki K, Matsuoka T, et al. Pulse methylprednisolone with gammagloblin as an initial treatment for acute Kawasaki disease. Eur J Pediatr. 2009;168(2):181–5.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomized, open-label, blinded-endpoints trial. Lancet. 2012;379(9826):1613–20.
   PubMed Web of Science ®Google Scholar